New developments in biochemical markers for osteoporosis

Calcified Tissue International

Volumn 59, Issue SUPPL. 1, 1996, Pages

  Garnero, P ^a   Delmas, P D ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; BIOCHEMICAL MARKER; OSTEOCALCIN; PROCOLLAGEN;

ALKALINE PHOSPHATASE BLOOD LEVEL; CALCIUM URINE LEVEL; HUMAN; MEDICAL RESEARCH; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

AGE FACTORS; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE REMODELING; FEMALE; HUMANS; OSTEOCALCIN; OSTEOPOROSIS; PROCOLLAGEN; PROGNOSIS;

EID: 0029805844     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002239900168     Document Type: Review

References (79)

1. Crilly RG, Jones MM, Horsman A, et al. (1980) Rise in plasma alkaline phosphatase at the menopause. Clin Sci 53: 341-342
2. Brown JP, Delmas PD, Arlot M, et al. (1987) Active bone turnover of the cortico-endosteal envelope in postmenopausal osteoporosis. J Clin Endocrinol Metab 64:954-959
3. Podenphant J, Johansen JS, Thomsen K, et al. (1987) Bone turnover in spinal osteoporosis. J Bone Miner Res 2:497-503
4. Moss DW (1982) Alkaline phosphatase isoenzymes. Clin Chem 28:2007-2016
5. Farley JR, Chesnut CJ, Baylink DJ (1981) Improved method for quantitative determination in serum alkaline phosphatase of skeletal origin. Clin Chem 27:2002-2007
6. Duda RJ, O'Brien JF, Katzmann JA, et al. (1988) Concurrent assays of circulating bone gla-protein and bone alkaline phosphatase: effects of sex, age, and metabolic bone disease. J Clin Endocrinol Metab 66:951-957
7. Hill CS, Wolfert RL (1986) The preparation of monoclonal antibodies which react preferentially with human bone alkaline phosphatase and not liver alkaline phosphatase. Clin Chem Acta 186:315-320
8. Garnero P, Delmas PD (1993) Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 77(4): 1046-1053
9. Price PA (1987) Vitamin K-dependent bone proteins. In: Cohn DV, Martin TJ, Meunier PJ (eds) Calcium regulation and bone metabolism. Basic and clinical aspects, vol 9. Elsevier Science Publishers, New York, pp 419-426
10. Price PA, Parthemore JG, Deftos JL (1980) New biochemical marker for bone metabolism. J Clin Invest 66:878-883
11. Price PA, Williamson MK, Lothringer JW (1981) Origin of vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone. J Biol Chem 256:12760-12766
12. Lian JB, Gundberg CM (1988) Osteocalcin: biochemical considerations and clinical applications. Clin Orthop 226:267-291
13. Delmas PD, Stenner D, Wahner HW, et al. (1983) Serum bone gla-protein increases with aging in normal women: implications for the mechanism of age-related bone loss. J Clin Invest 71:1316-1321
14. Thiede MA, Smock SL, Petersen DN, et al. (1994) Presence of messenger of ribonucleic acid encoding osteocalcin, a marker of bone turnover, in bone marrow megakaryocytes and peripheral blood platelets. Endocrinology 135:929-937
15. Delmas PD, Wilson DM, Mann KG, et al. (1983) Effect of renal function on plasma levels of bone gla-protein. J Clin Endocrinol Metab 57:1028-1030
16. Delmas PD (1990) Biochemical markers of bone turnover for the clinical assessment of metabolic disease. Endocrinol Metab Clin North Am 19(1):1-18
17. Brown JP, Delmas PD, Malaval L, et al. (1984) Serum bone gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet i:1091-1093
18. Charles P, Poser JW, Mosekilde L, et al. (1985) Estimation of bone turnover evaluated by 47 calcium kinetics: efficiency of serum bone gamma-carboxyglutamic acid containing protein, serum alkaline phosphatase and urinary hydroxyproline excretion. J Clin Invest 76:2254-2258
19. Delmas PD, Malaval L, Arlot ME, et al. (1985) Serum bone gla-protein compared to bone histomorphometry in endocrine diseases. Bone 6:329-341
20. Delmas PD, Demiaux B, Malaval L, et al. (1986) Serum bone gla-protein (osteocalcin) in primary hyperparathyroidism and in malignant hypercalcemias: comparison with bone histomorphometry. J Clin Invest 77:985-991
21. Bataille R, Delmas P, Sany J (1987) Serum bone gla-protein in multiple myeloma. Cancer 59:329-334
22. Gundberg C, Weinstein RS. Multiple immunoreactive forms in uremic serum (1986) J Clin Invest 77:1762-1767
23. Tracy RP, Andrianorivo A, Riggs BL, et al. (1990) Comparison of monoclonal and polyclonal antibody-based immunoassays for osteocalcin: a study of sources of variation in assay results. J Bone Miner Res 5:451-461
24. Taylor AK, Linkart S, Mohan S, et al. (1990) Multiple osteocalcin fragments in human urine and serum as detected by a midmolecule osteocalcin radioimmunoassay. J Clin Endocrinol Metab 70:467-472
25. Garnero P, Grimaux M, Seguin P, et al. (1994) Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res 9(2):255-264
26. Delmas PD, Christiansen C, Mann KG, et al. (1990) Bone gla-protein (osteocalcin) assay standardization report. J Bone Miner Res 1:5-11
27. Simon LS, Krane SMK (1983) Procollagen extension peptides as markers of collagen synthesis. In: Frame B, Potts JT Jr (eds) Clinical disorders of bone and mineral metabolism. Excerpta Medica, Amsterdam, the Netherlands, pp 108-111
28. Parfitt AM, Simon LS, Villanueva AR, et al. (1987) Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone: correlation with iliac bone formation rates and comparison with total alkaline phosphatase. J Bone Miner Res 2:427-436
29. Hassager C, Fabbri-Mabelli G, Christiansen C (1993) The effect of the menopause and hormone-replacement therapy on serum carboxyterminal propeptide of type I collagen. Osteoporos Int 3:50-52
30. Smedsrod B, Melkko J, Ristelli L, et al. (1990) Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem J 271:345-350
31. Prockop OJ, Kivirikko KI (1968) Hydroxyproline and the metabolism of collagen. In: Gould BS (ed) Treatise on collagen. Academic Press, New York, pp 215-246
32. Prockop OJ, Kivirikko KI, Tuderman K, et al. (1979) The biosynthesis of collagen and its disorders. N Engl J Med 301: 13-23
33. Krane SM, Kantrowitz FG, Byrne M, et al. (1977) Urinary excretion of hydroxylysine and its glycosides as an index of collagen degradation. J Clin Invest 59:819-827
34. Moro L, Mucelli RSP, Gazzarrini C, et al. (1988) Urinary β-1-galactosyl-O-hydroxylysine (GH) as a marker of collagen turnover of bone. Calcif Tissue Int 42:87-90
35. Li CY, Chuda RA, Lam WKW, et al. (1973) Acid phosphatase in human plasma. J Lab Clin Med 82:446-460
36. Minkin C (1982) Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int 34:285-290
37. Stepan JJ, Silinkova-Malkova E, Havrenek T, et al. (1983) Relationship of plasma tartrate-resistant acid phosphatase to the bone isoenzyme of serum alkaline phosphatase in hyperparathyroidism. Clin Chim Acta 133:189-200
38. Stepan JJ, Pospichal J, Presl J, et al. (1987) Bone loss and biochemical indices of bone remodeling in surgically induced postmenopausal women. Bone 8:279-284
39. Piedra C, Torres R, Rapado A, et al. (1989) Serum tartrateresistant acid phosphatase and bone mineral content in postmenopausal osteoporosis. Calcif Tissue Int 45:58-60
40. Kraenzlin M, Lau KHW, Liang L (1990) Development of an immunoassay for human serum osteoclastic tartrate-resistant acid phosphatase. J Clin Endocrinol Metab 71:442-451
41. Cheun CK, Panesar NS, Haines C, et al. (1995) Immunoassay of tartrate-resistant acid phosphatase in serum. Clin Chem 41:679-686
42. Fujimoto D, Morigachi T, Ishida T, et al. (1978) The structure of pyridinoline, a collagen crosslink. Biochem Biophys Res Commun 84:52-57
43. Eyre DR (1987) Collagen crosslinking amino-acids. Methods Enzymol 144:115-139
44. Eyre DR, Koob TJ, Van Ness KP (1984) Quantitation of hydroxypyridinium crosslinks in collagen by high-performance liquid chromatography. Anal Biochem 137:380-388
45. Eyre DR, Dickson IR, Van Ness KP (1988) Collagen crosslinking in human bone and articular cartilage: age-related changes in the content of mature hydroxypyridinium residues. Biochem J 252:495-500
46. Seibel MJ, Robins SP, Bilezikiau JP (1992) Urinary pyridinium crosslinks of collagen. Trends Endocrinol Metab 3: 263-270
47. Black D, Duncan A, Robins SP (1988) Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography. Anal Biochem 169:197-203
48. Beardsworth LJ, Eyre DR, Dickson IR (1990) Changes with age in the urinary excretion of lysyl and hydroxylysylpyridinoline, two new markers of bone collagen turnover. J Bone Miner Res 5:671-676
49. Uebelhart D, Schlemmer A, Johansen J, et al. (1991) Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium crosslinks. J Clin Endocrinol Metab 72:367-373
50. Eastell R, Hampton L, Colwell A (1990b) Urinary collagen crosslinks are highly correlated with radio isotopic measurements of bone resorption. In: Christiansen C, Overgaard K (eds) Proc 3rd Int Symp on Osteoporosis. Osteopress, Aalborg, Denmark, pp 469-470
51. Delmas PD, Schlemmer A, Gineyts E, et al. (1991) Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res 6:639-644
52. Uebelhart D, Gineyts E, Chapuy MC, et al. (1990) Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner Res 8: 87-96
53. Colwell A, Eastell R, Assiri AMA, et al. (1990) Effect of diet on deoxypyrinoline excretion, vol 2. In: Christiansen C, Overgaard K (eds) Osteoporosis. Osteopress, Aalborg, Denmark, pp 520-591
54. Schlemmer A, Hassager C, Jensen SB, et al. (1992) Marked diurnal variation in urinary excretion of pyridinium crosslinks in premenopausal women. J Clin Endocrinol Metab 74: 476-480
55. Eastell R, Calvo MS, Burritt MF, et al. (1992) Abnormalities in circadian patterns of bone resorption and renal calcium conservation in type I osteoporosis. J Clin Endocrinol Metab 74:487-494
56. Blumsohn A, Herrington K, Hannon RA, et al. (1994) The effect of calcium supplementation on the circadian rhythm of bone resorption. J Clin Endocrinol Metab 79:730-735
57. Seyedin S, Zuk R, Kung V, et al. (1993) An immunoassay to urinary pyridinoline: the new marker of bone resorption. J Bone Miner Res 8:635-642
58. Robins SP, Woitge H, Hesley R, et al. (1994) Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 9:1643-1649
59. Hanson DA, Weiss MAE, Bollen AM, et al. (1992) A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 7:1251-1258
60. Risteli J, Elomaa I, Niemi S, et al. (1993) Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 39:635-640
61. Bonde H, Quist P, Fidelins C, et al. (1994) Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 40:2022-2025
62. Delmas PD, Gineyts E, Bertholin A, et al. (1993) Immunoassay of pyridinoline crosslink excretion in normal adults and in Paget's disease. J Bone Miner Res 5:643-648
63. Garnero P, Gineyts E, Riou JP, et al. (1994) Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 3:780-785
64. Hassager C, Risteli J, Risteli L, et al. (1992) Diurnal variation in serum markers of type I collagen synthesis and degradation in healthy premenopausal women. J Bone Miner Res 7:1307-1311
65. Hassager C, Jensen LT, Podenphant J, et al. (1994) The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: the effect of nandrolone decanoate and hormone replacement therapy. CaIcif Tissue Int 54:30-33
66. Garnero P, Gineyts E, Arbault P, et al. (1995) Different effects of bisphosphonate and estrogen therapy on free and peptide-bound crosslinks excretion. J Bone Miner Res 10:641-649
67. Eastell R, Delmas PD, Hodgson SF, et al. (1988) Bone formation rate in older normal women: concurrent assessment with bone histomorphometry, calcium kinetics and biochemical markers. J Clin Endocrinol Metab 67:741-748
68. Garnero P, Sornay-Rendu E, Delmas PD, et al. (1996) Increased bone turnover in late postmenopausal women is a major risk of osteoporosis. J Bone Miner Res 11:337-349
69. Slemenda C, Hui SL, Longcope C, et al. (1987) Sex steroids and bone mass: a study of changes about the time of menopause. J Clin Invest 80:1261-1269
70. Johansen JS, Riis BJ, Delmas PD, et al. (1988) Plasma BGP: an indicator of spontaneous bone loss and effect of estrogen treatment in postmenopausal women. Eur J Clin Invest 18: 191-195
71. Hansen MA, Overgaard K, Riis BJ, et al. (1991) Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 years study. BMJ 303:961-964
72. Riis BJ, Hansen MA, Jensen K, et al. (1996) Low bone mass and fast rate of bone loss at menopause-equal risk factors for future fracture: a 15-year follow-up study. Bone 19:9-12
73. Thompson SP, White DA, Hosking DJ, et al. (1989) Changes in osteocalcin after femoral neck fracture. Ann Clin Biochem 26:487-491
74. Delmi M, Rapin CH, Bengoa JM, et al. (1990) Dietary supplementation in elderly patients with fractured neck of femur. Lancet 335:1013-1016
75. Akesson K, Vergnaud P, Gineyts E, et al. (1993) Impairment of bone turnover in elderly women with hip fracture. Calcif Tissue Int 53:162-169
76. Garnero P, Hausher E, Chapuy MC, et al. (1996) Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study. J Bone Miner Res (in press)
77. Civitelli R, Gonnelli S, Zacchei F, et al. (1988) Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. J Clin Invest 82:1268-1274
78. Garnero P, Shih WJ, Gineyts E, et al. (1994) Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700
79. Harris ET, Gertz BJ, Genant HK, et al. (1993) The effect of short-term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 76(6):1399-1403